Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Belle Health vs Lean Rx

Belle Health
Graded #48

Higher grade

vs+16.4
Lean Rx
Graded #318

Lower grade

The verdict

Belle Health takes it — 77/100 to 60.6/100.

Belle Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Belle Health is a national DTC telehealth platform offering compounded semaglutide and tirzepatide with flat-rate pricing — the same monthly cost at every dose, with no escalation surcharge as you titrate up.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBelle Health +52
92
40
Dose & formulationLean Rx +3
72
75
Clinical oversightLean Rx +10
71
81
Labs & monitoringBelle Health +20
72
52
FulfillmentBelle Health +25
85
60
Contract termsEven
55
55
Belle Health · left barLean Rx · right bar

The numbers

MetricBelle HealthLean Rx
WeighScore77/10060.6/100
GradeC+C
Scorecard rank#48#318
Semaglutide$119/mo$266/mo (starting dose, compounded)
Tirzepatide$199/mo (all doses, 3-month plan, compounded)$399/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Belle Health

Graded #48 · C+

Strengths

  • Five named compounding pharmacy partners disclosed (Striker, Strive, OptioRx, Enovex, Braun PharmaCare)
  • Flat-rate pricing — $119/mo semaglutide, $199/mo tirzepatide — doesn't rise at higher doses
  • Free weekly registered-dietitian sessions included
  • Operating since 2017
  • LegitScript Certified

Where it loses points

  • $199 tirzepatide price requires a 3-month bundle commitment
  • Compounded medications are not FDA-approved
  • Multi-pharmacy model — formulations may differ across orders
  • FDA issued this company a warning letter dated 20 February 2026; the letter is public in FDA's warning-letter database
Lean Rx

Graded #318 · C

Strengths

  • Both semaglutide and tirzepatide offered
  • Three formulations: injectable, sublingual, and tablet
  • Upfront pricing with no hidden fees advertised
  • Semaglutide starts at a low $266/month
  • Telehealth call with a licensed provider before prescribing

Where it loses points

  • Compounded-only; no FDA-approved branded options
  • No published state availability list
  • Platform is technology only, not a healthcare provider itself
  • Provider credentials not detailed on site

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard